Drug updated on 11/1/2024
Dosage Form | Injection (subcutaneous; 150 mg/mL) |
Drug Class | Interleukin-1β blockers |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of periodic fever syndromes: Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: Familial Cold Auto-inflammatory Syndorme (FCAS) and Muckle-Wells Syndrome (MWS)
- Indicated for the treatment of periodic fever syndromes: Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients
- Indicated for the treatment of periodic fever syndromes: Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients
- Indicated for the treatment of periodic fever syndromes: Familial Mediterranean Fever (FMF) in adult and pediatric patients
- Indicated for the treatment of Active Stills disease, including Adult-Onset Stills Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older
- Indicated for the treatment of Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.
Latest News
Summary
- This summary is based on the review of 13 systematic review(s)/meta-analysis(es). [1-13]
- In AOSD (Adult-onset Still's disease), canakinumab achieved complete remission in 68.7% of 99 patients and showed a complete remission rate of 77% (95% CI (confidence interval) 29-97%) with corticosteroid discontinuation in 34% (95% CI 6-81%), while effectiveness and safety were reported in refractory cases.
- For Gout Flares, canakinumab and rilonacept effectively reduced flare frequency and pain, with canakinumab providing the highest pain reduction by day 2 and at follow-up, outperforming corticosteroids and NSAIDs.
- In FMF, canakinumab was effective in 60% of adult patients and 81% of pediatric patients and likely reduced attack frequency in colchicine-resistant cases by 16 weeks.
- CAPS patients responded positively to canakinumab and other IL-1 blockers, with studies indicating effectiveness across IL-1 inhibitor options.
- AOSD: Among 69 patients treated with IL-1 inhibitors, 210 adverse events were reported, with respiratory tract infections, arthralgia, disease flares, abdominal pain, nausea, and diarrhea being common. Severe adverse events included macrophage activation syndrome and serious infections.
- Gout Flares: IL-1 inhibitors (canakinumab, anakinra, rilonacept) were mostly well-tolerated, with moderate certainty evidence suggesting canakinumab may have a superior safety profile compared to corticosteroids and NSAIDs.
- FMF: Adverse events occurred in 25% of adult patients and 12% of pediatric patients treated with canakinumab, with fewer serious adverse events compared to placebo in colchicine-resistant cases. Injection-site reactions were frequently observed for anakinra, rilonacept, and etanercept.
- Canakinumab demonstrated effectiveness across various populations, including adult and pediatric patients with conditions like AOSD, gout flares, FMF (with greater efficacy in pediatric FMF patients), and CAPS; IL-1 blockade during pregnancy showed no increase in adverse perinatal outcomes.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Ilaris (canakinumab) Prescribing Information. | 2023 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Adult-onset Still's disease: diagnosis and treatment according to the new S2e guidelines of the German Society of Rheumatology (DGRh). | 2023 | Die Dermatologie |